AstraZeneca shares fall on report of potential China probe fallout
Rewrites with AstraZeneca statement, details from report and background, change media key words to ASTRAZENECA-STOCKS
Nov 5 (Reuters) -AstraZeneca AZN.L shares on Tuesdayrecorded their worst daysince March 2020 after areport that dozens of the drugmaker's seniorexecutives in China couldbe implicated in the largest insurance fraud case in the country's pharma sector in years.
The Anglo-Swedish company, which has invested heavily in the world's No. 2 pharmaceuticals market,said last week that its China president, Leon Wang, was under investigation and that the drugmaker would cooperate with authorities.
AstraZeneca had not said what the investigation was about or whether Wang, who grew up in China and has been with the company for more than a decade, had been detained by authorities.
The investigation by Chinese authorities has now expanded to include the public security bureau, supervisory commission and other relevant bodies, financial media company Yicai reported on Tuesday, citing a person familiar with the matter.
The report added that medical representatives have been previously found to fake prescriptions for AstraZeneca's lung cancer drug, Tagrisso, to allow patients to buy it through the state's medical insurance program.
"As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China," AstraZeneca said.
"If requested, we will fully cooperate with the Chinese authorities," the company added and said that its operations and delivery of medicines were ongoing in China.
AstraZeneca is one of the biggest multinational drugmakers in China, which accounts for 13% of its overall revenue. It said last year it would build a $450 million factory in the country and has also signed several licensing deals with Chinese firms.
However, AstraZeneca's more than 30-year presence in the country has not been without challenges over prescriptions and sales.
In 2022, Chinese authorities had summoned AstraZeneca officials over an investigation of suspected medical insurance fraud by its employees, and had ordered that the drugmaker tighten its marketing activities.
The FTSE 100 .FTSE component fell as much as 8.4% on Tuesday tohit a seven-month low of 10,118 pence and was the second-biggest percentage loser on the blue-chip index.
Reporting by Aby Jose Koilparambil and Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva and Maju Samuel
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
